Clawing back: broadening the notion of metal chelators in medicine

Jones, 2007 Scott, 2009, Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease, Chem Rev, 109, 4885, 10.1021/cr9000176 Ala, 2007, Wilson's disease, Lancet, 369, 397, 10.1016/S0140-6736(07)60196-2 Walshe, 2003, The story of penicillamine: a difficult birth, Mov Disord, 18, 853, 10.1002/mds.10458 Bernhardt, 2007, Coordination chemistry and biology of chelators for the treatment of iron overload disorders, Dalton Trans, 3214, 10.1039/b708133b Baker, 2008, Mercury, vaccines, and autism, Am J Public Health, 98, 244, 10.2105/AJPH.2007.113159 Baxter, 2008, Pediatric fatality secondary to edta chelation, Clin Toxicol, 46, 1083, 10.1080/15563650701261488 Mitka, 2008, Chelation therapy trials halted, J Am Med Assoc, 300, 2236, 10.1001/jama.2008.607 Stangle, 2007, Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure, Environ Health Perspect, 115, 201, 10.1289/ehp.9263 Atwood, 2008, Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned, Medscape J Med, 10, 1 Ernst, 2000, Chelation therapy for coronary heart disease: an overview of all clinical investigations, Am Heart J, 140, 139, 10.1067/mhj.2000.107548 Shriver, Atkins, 2010 Haas, 2009, Application of metal coordination chemistry to explore and manipulate cell biology, Chem Rev, 109, 4921, 10.1021/cr900134a Duce, 2010, Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics, Prog Neurobiol, 92, 1, 10.1016/j.pneurobio.2010.04.003 Perez, 2010, Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease, Dalton Trans, 39, 2177, 10.1039/B919237A Braymer, 2011, Recent development of bifunctional small molecules to study metal-amyloid-β species in Alzheimer's disease, Int J Alzheimer Dis, 2011 Rodríguez-Rodríguez, 2012, The art of building multifunctional metal-binding agents from basic molecular scaffolds for the potential application in neurodegenerative diseases, Coord Chem Rev, 256, 2308, 10.1016/j.ccr.2012.03.008 Bareggi, 2012, Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders, CNS Neurosci Ther, 18, 41, 10.1111/j.1755-5949.2010.00231.x Cherny, 2001, Treatment with a copper–zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice, Neuron, 30, 665, 10.1016/S0896-6273(01)00317-8 Crouch, 2012, Therapeutic redistribution of metal ions to treat Alzheimer's disease, Acc Chem Res, 45, 1604, 10.1021/ar300074t Treiber, 2004, Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease, J Biol Chem, 279, 51958, 10.1074/jbc.M407410200 Jacobsen, 2010, Identifying chelators for metalloprotein inhibitors using a fragment-based approach, J Med Chem, 54, 591, 10.1021/jm101266s Agrawal, 2012, Probing chelation motifs in HIV integrase inhibitors, Proc Natl Acad Sci USA, 109, 2251, 10.1073/pnas.1112389109 Yu, 2006, Chelators at the cancer coalface: desferrioxamine to triapine and beyond, Clin Cancer Res, 12, 6876, 10.1158/1078-0432.CCR-06-1954 Aye, 2012, Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species, J Biol Chem, 287, 35768, 10.1074/jbc.M112.396911 Whitnall, 2006, A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics, Proc Natl Acad Sci USA, 103, 14901, 10.1073/pnas.0604979103 Richardson, 2006, Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity, J Med Chem, 49, 6510, 10.1021/jm0606342 Lovejoy, 2011, Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes, Cancer Res, 71, 5871, 10.1158/0008-5472.CAN-11-1218 O’Day, 2009, Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma, J Clin Oncol, 27, 5452, 10.1200/JCO.2008.17.1579 Nagai, 2012, The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells, Free Radic Biol Med, 52, 2142, 10.1016/j.freeradbiomed.2012.03.017 Blackman, 2012, Mitochondrial electron transport is the cellular target of the oncology drug elesclomol, PLoS ONE, 7, e29798, 10.1371/journal.pone.0029798 Charkoudian, 2006, A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation, J Am Chem Soc, 128, 12424, 10.1021/ja064806w Kielar, 2012, Prochelator BHAPI protects cells against paraquat-induced damage by ROS-triggered iron chelation, Metallomics, 4, 899, 10.1039/c2mt20069d Folk, 2010, A prochelator activated by beta-secretase inhibits Aβ aggregation and suppresses copper-induced reactive oxygen species formation, J Am Chem Soc, 132, 4994, 10.1021/ja100943r Zheng, 2010, Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities, ACS Chem Neurosci, 1, 737, 10.1021/cn100069c Zheng, 2010, Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy, ACS Chem Biol, 5, 603, 10.1021/cb900264w Scott, 2011, N-aryl-substituted 3-(β-d-glucopyranosyloxy)-2-methyl-4(1H)-pyridinones as agents for Alzheimer's therapy, Chem Sci, 2, 642, 10.1039/C0SC00544D Pujol, 2012, A sulfur tripod glycoconjugate that releases a high-affinity copper chelator in hepatocytes, Angew Chem Int Ed, 51, 7445, 10.1002/anie.201203255 Delangle, 2012, Chelation therapy in Wilson's disease: from d-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators, Dalton Trans, 41, 6359, 10.1039/c2dt12188c